Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682049 | 0.83 | ABCB1 (0.35) | TRPA1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL6681435 | 0.80 | THRB (0.43) | KMT2ASMN1; SMN2TSHRRAB9AKDM4E | |
| SCHEMBL6718675 | 0.79 | MAPT (0.51) | TRPA1RAB9ALMNAKDM4EALDH1A1 | |
| SCHEMBL6680635 | 0.79 | TRPA1 (0.41) | NOTUMTRPA1SMN1; SMN2TSHRPKM | |
| SCHEMBL6684992 | 0.77 | TRPA1 (0.39) | NOTUMTRPA1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL6685075 | 0.71 | TRPA1 (0.43) | TRPA1KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL7821723 | 0.66 | LMNA (0.50) | SMN1; SMN2TSHRLMNAFABP4KDM4E | |
| SCHEMBL6234824 | 0.66 | TRPA1 (0.49) | NOTUMTRPA1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL6679462 | 0.65 | ALDH1A1 (0.36) | TRPA1TSHRRAB9AKDM4EALDH1A1 | |
| SCHEMBL6680959 | 0.63 | ALDH1A1 (0.38) | TSHRRAB9AKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | claimed |
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004014354-A1 | 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | NOTUM 3582/4885TRPA1 4681/4885KMT2A 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.